- Home
- ANAB vs HIFS Comparison
ANAB vs HIFS Comparison
Compare ANAB & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- HIFS
- Stock Information
- Founded
- ANAB 2005
- HIFS 1834
- Country
- ANAB United States
- HIFS United States
- Employees
- ANAB N/A
- HIFS N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- HIFS Major Banks
- Sector
- ANAB Health Care
- HIFS Finance
- Exchange
- ANAB Nasdaq
- HIFS Nasdaq
- Market Cap
- ANAB 621.1M
- HIFS 611.4M
- IPO Year
- ANAB 2017
- HIFS N/A
- Fundamental
- Price
- ANAB $26.94
- HIFS $246.61
- Analyst Decision
- ANAB Buy
- HIFS
- Analyst Count
- ANAB 10
- HIFS 0
- Target Price
- ANAB $49.00
- HIFS N/A
- AVG Volume (30 Days)
- ANAB 526.3K
- HIFS 67.7K
- Earning Date
- ANAB 08-08-2025
- HIFS 07-11-2025
- Dividend Yield
- ANAB N/A
- HIFS 1.02%
- EPS Growth
- ANAB N/A
- HIFS 63.41
- EPS
- ANAB N/A
- HIFS 15.35
- Revenue
- ANAB $111,872,000.00
- HIFS $75,066,000.00
- Revenue This Year
- ANAB N/A
- HIFS N/A
- Revenue Next Year
- ANAB $24.39
- HIFS N/A
- P/E Ratio
- ANAB N/A
- HIFS $16.06
- Revenue Growth
- ANAB 387.20
- HIFS 37.00
- 52 Week Low
- ANAB $12.21
- HIFS $209.71
- 52 Week High
- ANAB $41.31
- HIFS $300.00
- Technical
- Relative Strength Index (RSI)
- ANAB 66.30
- HIFS 44.16
- Support Level
- ANAB $25.48
- HIFS $242.08
- Resistance Level
- ANAB $28.50
- HIFS $252.65
- Average True Range (ATR)
- ANAB 1.26
- HIFS 9.07
- MACD
- ANAB 0.02
- HIFS -3.51
- Stochastic Oscillator
- ANAB 70.23
- HIFS 8.92
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.